The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 20, 2023

Filed:

Nov. 23, 2021
Applicants:

Oregon Health & Science University, Portland, OR (US);

Pdx Pharmaceuticals, Inc., Portland, OR (US);

Inventors:

Wassana Yantasee, Lake Oswego, OR (US);

Moataz Reda, Portland, OR (US);

Worapol Ngamcherdtrakul, Portland, OR (US);

Assignees:

Oregon Health & Science University, Portland, OR (US);

PDX Pharmaceuticals, Inc., Portland, OR (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/14 (2006.01); A61K 31/519 (2006.01); A61K 47/68 (2017.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01); B82Y 5/00 (2011.01);
U.S. Cl.
CPC ...
A61K 9/143 (2013.01); A61K 9/146 (2013.01); A61K 31/519 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); A61K 47/6849 (2017.08); C07K 16/2827 (2013.01); A61K 9/0019 (2013.01); B82Y 5/00 (2013.01);
Abstract

Disclosed herein are therapeutic constructs including a delivery particle, at least one mitotic kinase inhibitor, and at least one immune checkpoint inhibitor. Also disclosed are therapeutic constructs including a mitotic kinase inhibitor, an immune checkpoint inhibitor, and a chemical linker. These therapeutic constructs cause cancer death by both therapeutic and immune effects and promote targeted delivery of more therapeutics to the surviving cancer cells in a positive feed-back loop. They enhance therapeutic index of free drugs and can be used intratumorally or systemically. This strategy can treat broad cancer types and is particular useful for cancer without obvious receptors for cancer-targeted delivery of otherwise toxic therapeutics.


Find Patent Forward Citations

Loading…